Characterization of WDR5 WIN-site Inhibition in Two Glioblastoma Cancer Stem Cell Models using Bulk RNAseq

WDR5 inhibitors have been implicated as a therapeutic vulnerability in glioblastoma cancer stem cells (CSCs). We tested the transcriptional effects of two different WDR5 WIN-site inhibitors, the dihydroisoquinoline C16 and the triazole C3TD078, in two CSC models (L0 and DI318) by bulk RNAseq.These data are associated with Coker et al., "Development and Characterization of Triazole-Based WDR5 Inhibitors for the Treatment of Glioblastoma," bioRxiv, 2025, https://doi.org/10.1101/2025.07.29.667410. Overall design: L0 and DI318 CSCs were treated for 72 hours with DMSO (0.1% v/v), 200 nM C16, or 200 nM C3TD078 (triplicate for all treatments). Total RNA was purified using a Qiagen RNeasy Plus kit and quality controlled for integrity and concentration on a Qubit® (Invitrogen). Bulk RNAseq was performed at MedGenome Inc. using the Illumina® Stranded mRNA Library Prep Kit and sequencing at 20M paired-end read-depth on a NovaSeq 6000 (PE100).